Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2044-5385
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide ; volume:9 ; number:4 ; day:20 ; month:3 ; year:2019 ; pages:1-8 ; date:4.2019
Blood cancer journal ; 9, Heft 4 (20.3.2019), 1-8, 4.2019
- Urheber
-
Moreau, Philippe
Zamagni, Elena
Mateos, Maria-Victoria
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-019-0200-1
- URN
-
urn:nbn:de:101:1-2019041401232496789667
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Moreau, Philippe
- Zamagni, Elena
- Mateos, Maria-Victoria
- SpringerLink (Online service)
Ähnliche Objekte (12)
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
Acute hypoxic respiratory failure due to Lenalidomide-induced interstitial pneumonitis in a patient with multiple myeloma
A gene signature can predict risk of MGUS progressing to multiple myeloma
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
Acute hypoxic respiratory failure due to Lenalidomide-induced interstitial pneumonitis in a patient with multiple myeloma
A gene signature can predict risk of MGUS progressing to multiple myeloma
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
Acute hypoxic respiratory failure due to Lenalidomide-induced interstitial pneumonitis in a patient with multiple myeloma